A new oral medication, orforglipron, is showing promise as a weight loss aid and for improving blood sugar control in people with type 2 diabetes. Published research in The Lancet details a phase 3 clinical trial demonstrating that orforglipron leads to greater reductions in blood glucose levels and significantly more weight loss compared to the currently available oral GLP-1 receptor agonist, semaglutide. This development offers a potential new option for individuals seeking alternatives to injectable medications and those who prefer not to restrict their food and fluid intake around medication timing.
Orforglipron belongs to a class of drugs called GLP-1 receptor agonists, which mimic the effects of a natural hormone that regulates appetite and blood sugar. Unlike existing oral semaglutide, which requires administration on an empty stomach, orforglipron can be taken with or without food, offering greater flexibility for patients. The study, known as Achieve-3, involved over 1,698 participants with type 2 diabetes across multiple countries – Argentina, China, Japan, Mexico and the United States – and compared the effects of orforglipron (at 12mg or 36mg doses) to semaglutide (at 7mg or 14mg doses) over a year-long period. The findings suggest a potential shift in how type 2 diabetes and obesity are managed, offering a more convenient and potentially effective treatment option.
Superior Glycemic Control and Weight Loss
The Achieve-3 trial revealed that participants taking orforglipron experienced a greater decrease in blood sugar levels across both dosage levels compared to those taking semaglutide. Specifically, the study showed improvements in HbA1c, a measure of long-term blood sugar control. In terms of weight loss, patients with an average starting weight of 97 kg (approximately 214 pounds) lost an average of 6-8% of their body weight with orforglipron, even as those on semaglutide experienced a 4-5% reduction. These results, as reported by Eli Lilly and Company, demonstrate a statistically significant advantage for orforglipron.
Balancing Efficacy with Side Effects
While orforglipron demonstrated promising results, it wasn’t without side effects. 9-10% of participants in the orforglipron groups discontinued treatment due to adverse events, primarily gastrointestinal issues, compared to 4-5% in the semaglutide groups. This highlights the importance of careful patient selection and monitoring when considering this medication. Gastrointestinal side effects are common with GLP-1 receptor agonists, but the higher rate of discontinuation with orforglipron suggests a need for further investigation into managing these effects. The study, lasting 52 weeks, rigorously assessed both the safety and efficacy of orforglipron in adults with type 2 diabetes whose condition wasn’t adequately controlled by metformin.
Cardiovascular Risk Factors and Orforglipron
Beyond blood sugar and weight management, the study also indicated positive effects on cardiovascular risk factors. Orforglipron showed improvements in key areas such as non-HDL cholesterol, HDL cholesterol, VLDL cholesterol, total cholesterol, systolic blood pressure, and triglycerides. These findings suggest that orforglipron may offer broader health benefits beyond glycemic control, potentially reducing the risk of cardiovascular disease, a common complication of type 2 diabetes. These improvements were clinically relevant compared to baseline levels, adding to the potential value of the medication.
Regulatory Review and Future Availability
Currently, orforglipron is under review by the U.S. Food and Drug Administration (FDA). Research published in November 2025 also explored orforglipron as a potential treatment for obesity, as an addition to lifestyle interventions. Eli Lilly anticipates an FDA decision regarding its use for obesity in the coming quarter. Kenneth Custer, Executive Vice President and President of Lilly Cardiometabolic Health, emphasized the potential benefits of orforglipron, stating that the combination of improved HbA1c reduction, weight loss, and the convenience of taking the medication without food or water restrictions “can build a significant difference for people managing their disease day to day.” Regulatory submissions have also been initiated internationally, signaling a broader effort to make this treatment option available to patients worldwide.
The development of orforglipron represents a significant step forward in the treatment of type 2 diabetes and potentially obesity. Its unique characteristics – oral administration and flexibility with meal timing – could improve adherence and patient satisfaction. However, the observed side effects warrant careful consideration and monitoring. The FDA’s upcoming decision will be a crucial milestone in determining the future availability of this promising new medication.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
What are your thoughts on this new medication? Share your comments below, and please share this article with anyone who might find it helpful.
